FDA Moves to Withdraw a Liquid Cholesterol Drug
Quick Facts
Why would the FDA withdraw approval of a cholesterol drug over missing reports?
After a medicine is approved, manufacturers are legally required to provide ongoing information to the FDA, including periodic safety and quality reports and any studies committed to as a condition of approval. These obligations let the agency monitor real-world safety, manufacturing consistency and continued benefit. When required reports are not delivered, the FDA has authority under the Federal Food, Drug, and Cosmetic Act to begin proceedings to withdraw an approval, typically offering the company an opportunity to respond or request a hearing.
According to Fierce Pharma and Cardiovascular Business, the agency has now taken this step for a liquid cholesterol-lowering drug. The reporting attributes the move to missing reports rather than a newly identified safety signal. That distinction matters: a procedural withdrawal reflects a compliance failure, though the FDA can also weigh whether the absence of data prevents it from confirming the drug remains safe and effective.
What should patients taking cholesterol-lowering medicine do now?
Elevated LDL cholesterol is a major modifiable risk factor for atherosclerotic cardiovascular disease, which remains a leading cause of death in the United States according to the CDC. Stopping lipid-lowering therapy abruptly can allow LDL levels to rise again, so any change should be planned. A proposed withdrawal is not an immediate recall, and the regulatory process can take time, including company responses and possible appeals.
Clinicians have many established alternatives, including statins, ezetimibe, bempedoic acid, PCSK9 inhibitors and other agents, and some are available in liquid or crushable forms for people who have difficulty swallowing tablets. Patients who rely on a liquid formulation for that reason should raise this with their prescriber early so a suitable substitute can be identified. The situation also illustrates why post-marketing reporting is a core part of drug safety oversight, not an administrative afterthought.
Frequently Asked Questions
Not necessarily. Reporting indicates the action concerns missing required reports. It is a regulatory step and does not by itself establish a new safety problem, though the FDA may consider whether the missing information affects its ability to assess the drug.
No. Continue taking it as prescribed unless your clinician or the FDA advises otherwise, and ask your doctor or pharmacist about availability and alternatives.
The agency can propose withdrawal, notify the manufacturer and offer an opportunity to respond or request a hearing before a final decision is made.
References
- Fierce Pharma. FDA moves to yank Salerno's liquid cholesterol drug approval on missing reports. November 2026.
- Cardiovascular Business. FDA wants cholesterol drug off the market. November 2026.
- Centers for Disease Control and Prevention. Heart Disease Facts.